CLAIMS

1. A peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, I, V, R, K, Q or L; X^2 is V, I, A, N, L or Q; X^3 is P; X^4 is Y, F or W; X^5 is D, N, Q or E; X^6 is Y, F , R, W, V, H, L, K or I; X^7 is N, S, G, D, H, E, Q or I; X^8 is W, L, F, M S, T, R, A, G, V, P, Y, I or K; X^9 is Y, N, F, K, L, R, I, V, W or Q; X^{10} is S, K, N, T, E, R, L, Q, I ,V, D, or K; X^{11} is N, E, D, Q, S, A or I; and X^{12} is W, R, V, L, I, K, F or E, wherein the peptide is not SVPYDYNWYSNW, and wherein said peptide is a cyclic peptide.

2. A peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, T, K, R, H, E, I, Q or D; X^2 is V, I, L, Y, G, F or W; X^3 is H, N, Q, E, D or S; X^4 is S, P, A or T; X^5 is F, W or Y; X^6 is D, N, E or Q; X^7 is Y, F or W; X^8 is D, G or E; X^9 is W, F or Y; X^{10} is Y, F or W; X^{11} is N or Q; and X^{12} is V, I or L, wherein the peptide is not SVHSFDYDWYNV, and wherein said peptide is a cyclic peptide.

3. The peptide of one of the preceding claims, wherein the peptide is SVPFDYNLYSNW; SAPYNFNFYSNW; NIPFNFSLNKER; SVPYQYNWYSNW; SVPWEYNFYSNW; RIPYDRGMIVNV; KVPYDWDSVINL; QLPYDVHTYNDW; LAPYDHNRYTQW; SNPYDLEAYENW; SVPYDYQGYRNI; SVPYDYNVYLNK; IQPYDKNYFQNF; VVPYDINIKDNW; SVPYDYNPYSNW; SVPYDYNKLKNW; SVPYDYNWRSSW; SVPYDYNWWSAW; SVPYDYNWQSNW; ELSSFNFDWYNV; RYSSFDYDWYNV; NVHSFDYDWYNV; RVESFNYDWYNV; RVESFDFDWYNI; RINSFDYDWYNV; TVNSFDYDWYNV; KVNSFDYDWYNV; TVHSFDYDWYNV; SVHSWDYDWYNV; SVHSYDFDWYNV; TLQAFNYEWYQL; KYETFEYGWYNI; HGDSFQYEWYNL; SVHSFDWDWYNV; SVHSFDYDYYNV; SVHSFDYDFYNV; SVHSFDYDWFNV; SVHSFDYDWWNV; IFNPFDYDWYNV; QWHSFDYDWYNV or DVHPFDYDWYNV, and wherein said peptide is a cyclic peptide.

4. The peptide of one of the preceding claims, wherein said peptide is soluble.

5. The peptide of one of the preceding claims, wherein said peptide is attached to a linker.

6. The peptide of claim 5, wherein said linker is polyethylene glycol or palmitic acid.

7. The peptide of one of the preceding claims, wherein the peptide is synthetic.

8. A composition comprising a protein or peptide according to any one of the preceding claims, wherein said composition is capable of detaching a single cell organism from a surface or from other single cell organisms.

9. The composition of claim 8, wherein said protein or peptide is from a human or aquatic organism.

10. The composition of claim 8, wherein said peptide consists of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, I, V, R, K, Q or L; X^2 is V, I, A, N, L or Q; X^3 is P; X^4 is Y, F or W; X^5 is D, N, Q or E; X^6 is Y, F , R, W, V, H, L, K or I; X^7 is N, S, G, D, H, E, Q or I; X^8 is W, L, F, M, S, T, R, A, G, V, P, Y, I or K; X^9 is Y, N, F, K, L, R, I, V, W or Q; X^{10} is S, K, N, T, E, R, L, Q, I ,V, D, or K; X^{11} is N, E, D, Q, S, A or I; and X^{12} is W, R, V, L, I, K, F or E, wherein the peptide is not SVPYDYNWYSNW.

11. The composition of claim 8, wherein said peptide consists of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, T, K, R, H, E, I, Q or D; X^2 is V, I, L, Y, G, F or W; X^3 is H, N, Q, E, D or S; X^4 is S, P, A or T; X^5 is F, W or Y; X^6 is D, N, E or Q; X^7 is Y, F or W; X^8 is D, G or E; X^9 is W, F or Y; X^{10} is Y, F or W; X^{11} is N or Q; and X^{12} is V, I or L, wherein the peptide is not SVHSFDYDWYNV.

12. The composition of claim 10 or 11, wherein the peptide is SVPFDYNLYSNW; SAPYNFNFYSNW; NIPFNFSLNKER; SVPYQYNWYSNW;

SVPWEYNFYSNW; RIPYDRGMIVNV; KVPYDWDSVINL; QLPYDVHTYNDW; LAPYDHNRYTQW; SNPYDLEAYENW; SVPYDYQGYRNI; SVPYDYNVYLNK; IQPYDKNYFQNF; VVPYDINIKDNW; SVPYDYNPYSNW; SVPYDYNKLKNW; SVPYDYNWRSSW; SVPYDYNWWSAW; SVPYDYNWQSNW; ELSSFNFDWYNV; RYSSFDYDWYNV; NVHSFDYDWYNV; RVESFNYDWYNV; RVESFDFDWYNI; RINSFDYDWYNV; TVNSFDYDWYNV; KVNSFDYDWYNV; TVHSFDYDWYNV; SVHSWDYDWYNV; SVHSYDFDWYNV; TLQAFNYEWYQL; KYETFEYGWYNI; HGDSFQYEWYNL; SVHSFDWDWYNV; SVHSFDYDYYNV; SVHSFDYDFYNV; SVHSFDYDWFNV; SVHSFDYDWWNV; IFNPFDYDWYNV; QWHSFDYDWYNV or DVHPFDYDWYNV, and wherein said peptide is a cyclic peptide.

13. The composition of one of claims 8-12, wherein said peptide is soluble.

14. The composition of one of claims 8-13, wherein said peptide is attached to a linker.

15. The composition of claim 14, wherein said linker is polyethylene glycol or palmitic acid.

16. The composition of one of claims 8-15, wherein the peptide is synthetic.

17. The composition of one of claims 8-16, wherein said organism is in a biofilm.

18. The composition of one of claims 8-17, wherein said organism is an aquatic organism.

19. The composition of one of claims 8-18, wherein said organisms are attached in a cluster or aggregate.

20. The composition of one of claims 8-19, wherein said composition is capable of breaking or dispersing said cluster or aggregate.

21. The composition of one of claims 8-20, wherein said detaching affects the ability of said organism to produce polysaccharide matrix.

22. The composition of one of claims 8-21, wherein said surface is a selected from the group comprising a fabric, a fiber, a foam, a film, a concrete, a masonry, a glass, a metal and a plastic.

23. The method of of detaching a single cell organism from a surface or from other single cell organisms, comprising contacting said organism with a composition comprising a protein or peptide, wherein said peptide consists of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, I, V, R, K, Q or L; X^2 is V, I, A, N, L or Q; X^3 is P; X^4 is Y, F or W; X^5 is D, N, Q or E; X^6 is Y, F , R, W, V, H, L, K or I; X^7 is N, S, G, D, H, E, Q or I; X^8 is W, L, F, M S, T, R, A, G, V, P, Y, I or K; X^9 is Y, N, F, K, L, R, I, V, W or Q; X^{10} is S, K, N, T, E, R, L, Q, I ,V, D, or K; X^{11} is N, E, D, Q, S, A or I; and X^{12} is W, R, V, L, I, K, F or E, wherein the peptide is not SVPYDYNWYSNW , and wherein said peptide is a cyclic peptide.

24. The method of of detaching a single cell organism from a surface or from other single cell organisms, comprising contacting said organism with a composition comprising a protein or peptide, wherein said peptide consists of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, T, K, R, H, E, I, Q or D; X^2 is V, I, L, Y, G, F or W; X^3 is H, N, Q, E, D or S; X^4 is S, P, A or T; X^5 is F, W or Y; X^6 is D, N, E or Q; X^7 is Y, F or W; X^8 is D, G or E; X^9 is W, F or Y; X^{10} is Y, F or W;

X^{11} is N or Q; and X^{12} is V, I or L, wherein the peptide is not SVHSFDYDWYNV, and wherein said peptide is a cyclic peptide.

25. The method of one of claims 23-24, wherein the peptide is SVPFDYNLYSNW; SAPYNFNFYSNW; NIPFNFSLNKER; SVPYQYNWYSNW; SVPWEYNFYSNW; RIPYDRGMIVNV; KVPYDWDSVINL; QLPYDVHTYNDW; LAPYDHNRYTQW; SNPYDLEAYENW; SVPYDYQGYRNI; SVPYDYNVYLNK; IQPYDKNYFQNF; VVPYDINIKDNW; SVPYDYNPYSNW; SVPYDYNKLKNW; SVPYDYNWRSSW; SVPYDYNWWSAW; SVPYDYNWQSNW; ELSSFNFDWYNV; RYSSFDYDWYNV; NVHSFDYDWYNV; RVESFNYDWYNV; RVESFDFDWYNI; RINSFDYDWYNV; TVNSFDYDWYNV; KVNSFDYDWYNV; TVHSFDYDWYNV; SVHSWDYDWYNV; SVHSYDFDWYNV; TLQAFNYEWYQL; KYETFEYGWYNI; HGDSFQYEWYNL; SVHSFDWDWYNV; SVHSFDYDYYNV; SVHSFDYDFYNV; SVHSFDYDWFNV; SVHSFDYDWWNV; IFNPFDYDWYNV; QWHSFDYDWYNV or DVHPFDYDWYNV , and wherein said peptide is a cyclic peptide.

26. The method of one of claims 23-25, wherein said peptide is soluble.

27. The method of one of claims 23-26, wherein said peptide is attached to a linker.

28. The method of claim 27, wherein said linker is polyethylene glycol or palmitic acid.

29. The method of one of claims 23-28, wherein the peptide is synthetic.

30. The method of one of claims 23-29, wherein said surface is selected from the group comprising a fabric, a fiber, a foam, a film, a concrete, a masonry, a glass, a metal and a plastic.

31. The method of one of claims 23-30, wherein said organism is in a biofilm.

32. The method of one of claims 23-31, wherein said organism is an aquatic organism.

33. The method of one of claims 23-32, wherein said organisms are attached in a cluster or aggregate.

34. The method of one of claims 23-33, wherein said composition breaks or disperses said cluster or aggregate.

35. The method of one of claims 23-34, wherein said composition prevents said organism from producing polysaccharide matrix.

36. The method of one of claims 23-35, wherein said surface is a selected from the group comprising a fabric, a fiber, a foam, a film, a concrete, a masonry, a glass, a metal and a plastic.

37. A pharmaceutical composition comprising the composition of one of claims 8-22 and a pharmaceutically acceptable carrier or diluent.

38. The pharmaceutical composition according to claim 37 for use in a method of preventing or treating a pathogen infection in a subject in need thereof, wherein the pharmaceutical composition of claim 37 is for administering to the subject in a therapeutically effective amount.

39. The composition of one of claims 8-22 for use in a method of increasing the effectiveness of a pharmaceutical composition, wherein the composition of one of claims 9-24 is for administering to a subject in need of the pharmaceutical composition.

40. The composition for the use of claim 39, wherein said pharmaceutical composition is an antibiotic.

41. A method of identifying an anti-biofilm composition, the method comprising

(a) contacting said biofilm with a plurality of compositions, each composition comprising a protein or peptide;

(b) assaying the ability of said biofilm to resist anti-bioflim activity, wherein said anti-bioflim activity comprises detaching said biofilm from a surface or breaking up said biofilm; and

(c) identifying from said plurality of compositions at least one composition having said anti-biofilm activity above a predetermined threshold, thereby identifying the anti-biofilm composition.

42. The method of claim 41, wherein the peptide is SVPFDYNLYSNW; SAPYNFNFYSNW; NIPFNFSLNKER; SVPYQYNWYSNW; SVPWEYNFYSNW; RIPYDRGMIVNV; KVPYDWDSVINL; QLPYDVHTYNDW; LAPYDHNRYTQW; SNPYDLEAYENW; SVPYDYQGYRNI; SVPYDYNVYLNK; IQPYDKNYFQNF; VVPYDINIKDNW; SVPYDYNPYSNW; SVPYDYNKLKNW; SVPYDYNWRSSW; SVPYDYNWWSAW; SVPYDYNWQSNW; ELSSFNFDWYNV; RYSSFDYDWYNV; NVHSFDYDWYNV; RVESFNYDWYNV; RVESFDFDWYNI; RINSFDYDWYNV; TVNSFDYDWYNV; KVNSFDYDWYNV; TVHSFDYDWYNV; SVHSWDYDWYNV; SVHSYDFDWYNV; TLQAFNYEWYQL; KYETFEYGWYNI; HGDSFQYEWYNL; SVHSFDWDWYNV; SVHSFDYDYYNV; SVHSFDYDFYNV; SVHSFDYDWFNV; SVHSFDYDWWNV; IFNPFDYDWYNV; QWHSFDYDWYNV or DVHPFDYDWYNV, and wherein said peptide is a cyclic peptide.

43. A medical device comprising the composition of one of claims 8-22.

44. A method of dispersing a biofilm or detaching biofilm formation from a surface, the method comprising treating water with or coating said surface with the composition of one of claims 8-22.

45. A peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, I, V, R, K, Q or L; X^2 is V, I, A, N, L or Q; X^3 is P; X^4 is Y, F or W; X^5 is D, N, Q or E; X^6 is Y, F , R, W, V, H, L, K or I; X^7 is N, S, G, D, H, E, Q or I; X^8 is W, L, F, M S, T, R, A, G, V, P, Y, I or K; X^9 is Y, N, F, K, L, R, I, V, W or Q; X^{10} is S, K, N, T, E, R, L, Q, I ,V, D, or K; X^{11} is N, E, D, Q, S, A or I; and X^{12} is W, R, V, L, I, K,

F or E, wherein the peptide is not SVPYDYNWYSNW, and wherein said peptide is a cyclic peptide,for use in a method of treating a disease, wherein said peptide is for administering to a subject.

46. A peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, T, K, R, H, E, I, Q or D; X^2 is V, I, L, Y, G, F or W; X^3 is H, N, Q, E, D or S; X^4 is S, P, A or T; X^5 is F, W or Y; X^6 is D, N, E or Q; X^7 is Y, F or W; X^8 is D, G or E; X^9 is W, F or Y; X^{10} is Y, F or W; X^{11} is N or Q; and X^{12} is V, I or L, wherein the peptide is not SVHSFDYDWYNV, and wherein said peptide is a cyclic peptide, for use in a method of treating a disease, wherein said peptide is for administering to a subject.

47. The peptide for the use of one of claims 45-46, wherein the disease is autoimmune, inflammatory or degenerative disease.

48. The peptide for the use of claim 47, wherein the disease is Alzheimer's Disease.

49. A peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, I, V, R, K, Q or L; X^2 is V, I, A, N, L or Q; X^3 is P; X^4 is Y, F or W; X^5 is D, N, Q or E; X^6 is Y, F , R, W, V, H, L, K or I; X^7 is N, S, G, D, H, E, Q or I; X^8 is W, L, F, M S, T, R, A, G, V, P, Y, I or K; X^9 is Y, N, F, K, L, R, I, V, W or Q; X^{10} is S, K, N, T, E, R, L, Q, I ,V, D, or K; X^{11} is N, E, D, Q, S, A or I; and X^{12} is W, R, V, L, I, K, F or E, wherein the peptide is not SVPYDYNWYSNW, and wherein said peptide is a cyclic peptide,for use in a method of reducing restenosis, wherein said peptide is for administering to a subject.

50. A peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, T, K, R, H, E, I, Q or D; X^2 is V, I, L, Y, G, F or W; X^3 is H, N, Q, E, D or S; X^4 is S, P, A or T; X^5 is F, W or Y; X^6 is D, N, E or Q; X^7 is Y, F or W; X^8 is D, G or E; X^9 is W, F or Y; X^{10} is Y, F or W; X^{11} is N or Q; and X^{12} is V, I or L, wherein the peptide is not SVHSFDYDWYNV, and wherein said peptide is a cyclic peptide,for use in a method of reducing restenosis, wherein said peptide is for administering to a subject.

51. A peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, I, V, R, K, Q or L; X^2 is V, I, A, N, L or Q; X^3 is P; X^4 is Y, F or W; X^5 is D, N, Q or E; X^6 is Y, F , R, W, V, H, L, K or I; X^7 is N, S, G, D, H, E, Q or I; X^8 is W, L, F, M S, T, R, A, G, V, P, Y, I or K; X^9 is Y, N, F, K, L, R, I, V, W or Q; X^{10} is S, K, N, T, E, R, L, Q, I ,V, D, or K; X^{11} is N, E, D, Q, S, A or I; and X^{12} is W, R, V, L, I, K, F or E, wherein the peptide is not SVPYDYNWYSNW, and wherein said peptide is a cyclic peptide, for use in a method of reducing white blood cell clustering, wherein said peptide is for administering to a subject.

52. A peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, T, K, R, H, E, I, Q or D; X^2 is V, I, L, Y, G, F or W; X^3 is H, N, Q, E, D or S; X^4 is S, P, A or T; X^5 is F, W or Y; X^6 is D, N, E or Q; X^7 is Y, F or W; X^8 is D, G or E; X^9 is W, F or Y; X^{10} is Y, F or W; X^{11} is N or Q; and X^{12} is V, I or L, wherein the peptide is not SVHSFDYDWYNV, and wherein said peptide is a cyclic peptide,for use in a method of reducing white blood cell clustering, wherein said peptide is for administering to a subject.

53. Use of a therapeutically effective amount of the composition of one of claims 8-22 in the preparation of a medicament for preventing or treating a pathogen infection in a subject.

54. Use of the composition of one of claims 8-22 in the preparation of a medicament for administering to a subject in need of a pharmaceutical composition to enhance the effectiveness of said pharmaceutical composition.

55. Use according to claim 54, wherein the pharmaceutical composition is an antibiotic.

56. Use of a peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, I, V, R, K, Q or L; X^2 is V, I, A, N, L or Q; X^3 is P; X^4 is Y, F or W; X^5 is D, N, Q or E; X^6 is Y, F , R, W, V, H, L, K or I; X^7 is N, S, G, D, H, E, Q or I; X^8 is W, L, F, M S, T, R, A, G, V, P, Y, I or K; X^9 is Y, N, F, K, L, R, I, V, W or Q; X^{10} is S, K, N, T, E, R, L, Q, I ,V, D, or K; X^{11} is N, E, D, Q, S, A or I; and X^{12} is W, R,

V, L, I, K, F or E, wherein the peptide is not SVPYDYNWYSNW, and wherein said peptide is a cyclic peptide,for the preparation of a medicament for treating a disease.

57. Use of a peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, T, K, R, H, E, I, Q or D; X^2 is V, I, L, Y, G, F or W; X^3 is H, N, Q, E, D or S; X^4 is S, P, A or T; X^5 is F, W or Y; X^6 is D, N, E or Q; X^7 is Y, F or W; X^8 is D, G or E; X^9 is W, F or Y; X^{10} is Y, F or W; X^{11} is N or Q; and X^{12} is V, I or L, wherein the peptide is not SVHSFDYDWYNV, and wherein said peptide is a cyclic peptide,for the preparation of a medicament for treating a disease.

58. Use according to one of claims 56-57, wherein the disease is autoimmune, inflammatory or degenerative disease.

59. Use according to claim 58, wherein the disease is Alzheimer's Disease.

60. Use of a peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, I, V, R, K, Q or L; X^2 is V, I, A, N, L or Q; X^3 is P; X^4 is Y, F or W; X^5 is D, N, Q or E; X^6 is Y, F, R, W, V, H, L, K or I; X^7 is N, S, G, D, H, E, Q or I; X^8 is W, L, F, M S, T, R, A, G, V, P, Y, I or K; X^9 is Y, N, F, K, L, R, I, V, W or Q; X^{10} is S, K, N, T, E, R, L, Q, I ,V, D, or K; X^{11} is N, E, D, Q, S, A or I; and X^{12} is W, R, V, L, I, K, F or E, wherein the peptide is not SVPYDYNWYSNW, and wherein said peptide is a cyclic peptide, for the preparation of a medicament for reducing restenosis.

61. Use of a peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, I, V, R, K, Q or L; X^2 is V, I, A, N, L or Q; X^3 is P; X^4 is Y, F or W; X^5 is D, N, Q or E; X^6 is Y, F , R, W, V, H, L, K or I; X^7 is N, S, G, D, H, E, Q or I; X^8 is W, L, F, M S, T, R, A, G, V, P, Y, I or K; X^9 is Y, N, F, K, L, R, I, V, W or Q; X^{10} is S, K, N, T, E, R, L, Q, I ,V, D, or K; X^{11} is N, E, D, Q, S, A or I; and X^{12} is W, R, V, L, I, K, F or E, wherein the peptide is not SVPYDYNWYSNW, and wherein said peptide is a cyclic peptide, for the preparation of a medicament for reducing white blood cell clustering.

62. Use of a peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, T, K, R, H, E, I, Q or D; X^2 is V, I, L, Y, G, F or W; X^3 is H, N, Q, E, D or S; X^4 is S, P, A or T; X^5 is F, W or Y; X^6 is D, N, E or Q; X^7 is Y, F or W; X^8 is D, G or E; X^9 is W, F or Y; X^{10} is Y, F or W; X^{11} is N or Q; and X^{12} is V, I or L, wherein the peptide is not SVHSFDYDWYNV, and wherein said peptide is a cyclic peptide, for preparation of a medicament for reducing white blood cell clustering.

CLAIMS

1. A cyclic peptide consisting of: a) the amino acid sequence X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, T, K, R, H, E, I, Q or D; X^2 is V, I, L, Y, G, F or W; X^3 is H, N, Q, E, D or S; X^4 is S, P, A or T; X^5 is F, W or Y; X^6 is D, N, E or Q; X^7 is Y, F or W; X^8 is D, G or E; X^9 is W, F or Y; X^{10} is Y, F or W; X^{11} is N or Q; and X^{12} is V, I or L; and b) a cyclization linker between X^1 and X^{12}, wherein the peptide is not SVHSFDYDWYNV, and wherein the cyclic peptide has a total length of up to 50 amino acids.

2. The peptide according to claim 1, wherein the amino acid sequence is selected from the group consisting of SVHSWDYDWYNV, SVHSYDFDWYNV, TLQAFNYEWYQL, KYETFEYGWYNI, HGDSFQYEWYNL, SVHSFDWDWYNV, SVHSFDYDYYNV, SVHSFDYDFYNV, SVHSFDYDWFNV, SVHSFDYDWWNV, IFNPFDYDWYNV, QWHSFDYDWYNV, and DVHPFDYDWYNV.

3. The cyclic peptide according to claim 1, wherein the cyclization linker comprises two amino acids independently selected from the group consisting of natural or non-natural amino acids.

4. The cyclic peptide according to claim 3, wherein the cyclization linker comprises two cysteines.

5. The cyclic peptide according to claim 4, wherein the cyclization linker consists of two cysteines.

6. A composition comprising a peptide according to claim 1.

7. A method of detaching a single cell organism from a surface or from other single cell organisms, comprising contacting said organism with a composition according to claim 6.

8. A method of dispersing a biofilm in water or detaching biofilm formation from a surface, comprising treating the water with or coating said surface with a composition according to claim 6.